Plan & O2C Lead – MedTech Dynamo Deployment

Johnson & Johnson Co.; United States; Hybrid; USD 94,000 - 152,000; Full time

Benefits offered by this job

Long-term incentive program

401(k) retirement plan

Paid time off and benefits

Job summary

Johnson & Johnson, a global health leader, seeks a Plan WorkStream Team Lead for MedTech Transcend Dynamo Deployment. The role focuses on aligning order-to-cash templates with NA business processes and ensuring readiness for deployment.

Based primarily in Raritan, NJ, remote work may be considered case-by-case for US-based candidates. The contract is duration-based, with a projected end around March 2029, and includes severance eligibility and extensive benefits.

Qualifications

• Minimum three years of experience in Supply Chain or Order to Cash processes.
• Subject-matter expertise in Plan and Order-to-Cash capabilities within an SAP environment.
• Proficiency with SAP modules relevant to value stream: Allocation Management, Inventory Planning, Order Fulfillment.

Responsibilities

• Participate in solution confirmation workshops ensuring alignment to order management and plan requirements.
• Serve as a plan business representative providing guidance on global, local, and specialized process requirements.
• Lead validation activities for the plan workstream through integrated testing and business simulations.
• Define and govern plan test scenarios to support end-to-end O2C validation.
• Oversee plan data readiness including data cleansing, validation, and deployment preparedness.

Skills

Supply Chain

Order to Cash

SAP OTC

Data analysis

Decision making under ambiguity

Education

Bachelor’s degree

Tools

SAP ERP

Job description

Johnson & Johnson, a global health leader, seeks a Plan WorkStream Team Lead for MedTech Transcend Dynamo Deployment. The role focuses on aligning order-to-cash templates with NA business processes and ensuring readiness for deployment.

Based primarily in Raritan, NJ, remote work may be considered case-by-case for US-based candidates. The contract is duration-based, with a projected end around March 2029, and includes severance eligibility and extensive benefits.